Pulse Biosciences, Inc. (PLSE)

NASDAQ: PLSE · Real-Time Price · USD
16.31
+1.12 (7.38%)
Nov 5, 2024, 1:23 PM EST - Market open
7.38%
Market Cap 1.00B
Revenue (ttm) n/a
Net Income (ttm) -46.13M
Shares Out 61.52M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 47,439
Open 15.23
Previous Close 15.19
Day's Range 15.21 - 16.60
52-Week Range 4.57 - 22.69
Beta 1.75
Analysts n/a
Price Target n/a
Earnings Date Oct 30, 2024

About PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporat... [Read more]

Sector Healthcare
IPO Date May 18, 2016
Employees 56
Stock Exchange NASDAQ
Ticker Symbol PLSE
Full Company Profile

Financial Performance

Financial Statements

News

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positi...

5 days ago - Business Wire

Pulse Biosciences, Inc. (PLSE) Q3 2024 Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations Burke Barrett - President & Chief Executive Of...

5 days ago - Seeking Alpha

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-P...

5 days ago - Business Wire

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of...

5 days ago - Business Wire

Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report fin...

15 days ago - Business Wire

Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript

Pulse Biosciences Inc. (NASDAQ:PLSE) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffle...

3 months ago - Seeking Alpha

Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) techn...

3 months ago - Business Wire

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technol...

3 months ago - Business Wire

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technol...

3 months ago - Business Wire

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technol...

3 months ago - Business Wire

Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report fin...

3 months ago - Business Wire

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technol...

4 months ago - Business Wire

Pulse Biosciences, Inc. Announces the Closing of its Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation...

4 months ago - Business Wire

Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation...

4 months ago - Business Wire

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation...

5 months ago - Business Wire

Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) t...

6 months ago - Business Wire

Pulse Biosciences' CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...

6 months ago - Business Wire

Pulse Biosciences Enhances Executive Leadership Team

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology (“Pulse”), today ...

6 months ago - Business Wire

Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript

Pulse Biosciences Inc (NASDAQ:PLSE) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Philip Taylor - Principal, Gilmartin Group LLC Kevin Danahy - President & CEO Michael ...

6 months ago - Seeking Alpha

Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...

6 months ago - Business Wire

Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...

6 months ago - Business Wire

Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) t...

6 months ago - Business Wire

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...

6 months ago - Business Wire

Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript

Pulse Biosciences Inc (PLSE) Q4 2023 Earnings Call Transcript

7 months ago - Seeking Alpha

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...

7 months ago - Business Wire